Loading stock data…
SYK
$282.58-2.89 (-1.01%)
Market ClosedLast close May 11
Stryker Corporation operates as a medical technology company in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Stryker Corporation in the Healthcare sector is trading at $282.58. The stock is currently near its 52-week low of $281.00, remaining 21.5% below its 200-day moving average. Technical signals show oversold RSI of 16 and bearish MACD signal, explaining why SYK maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 16) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$282.58
Potential Downside
46%
Whystock Fair Value$152.58
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus26 analysts
Buy
Mean target$392.19+38.8%
Range$315.00 – $465.00
Fundamentals
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$124.65B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
38.70
Beta
Defensive asset. Lower volatility than the S&P 500.
0.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.22%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.48%
Volume
Today's trading volume
2.14M
Recent News
Stryker's (NYSE:SYK) Earnings Offer More Than Meets The Eye
Despite posting healthy earnings, Stryker Corporation's ( NYSE:SYK ) stock has been quite weak. Our analysis suggests...
Stryker closes Amplitude Vascular acquisition
With an intravascular lithotripsy platform, Stryker will enter a booming market that has attracted investment from Johnson & Johnson, Boston Scientific and Abbott.
Mercury Systems Q3 Earnings Call Highlights
Mercury Systems (NASDAQ:MRCY) reported third-quarter fiscal 2026 results that exceeded management’s expectations, driven by stronger-than-planned backlog conversion, record bookings, and year-over-year margin expansion. Chairman and CEO Bill Ballhaus said the quarter reflected “strong demand signals
Stryker Reshapes Portfolio With Ortho Tech Push And Vascular Acquisition
Stryker (NYSE:SYK) announced plans to acquire Amplitude Vascular Systems, expanding its cardiovascular device portfolio. The company introduced a new Ortho Tech segment, highlighting adoption of its Mako and Pangea platforms. These moves come as Stryker continues to address a recent cyber incident and looks beyond near term earnings effects. Stryker enters this phase of portfolio reshaping with its stock at $290.88 and a mixed return profile. The share price is down 11.6% over the past...
SYK Q1 Deep Dive: Cyber Incident Disrupts Operations, Management Reiterates Full-Year Outlook
Medical technology company Stryker (NYSE:SYK) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.6% year on year to $6.02 billion. Its non-GAAP profit of $2.60 per share was 12.9% below analysts’ consensus estimates.